- Clinical Trials
Company overview to highlight novel gene therapies for cancer and diabetes
What will it take to transition gene therapy from a treatment for diseases that only affect a few hundred thousand people worldwide to Type 1 diabetes, which is estimated to affect more than 45 million?
Two Featured Presentations will Highlight Potential of TUSC2 Immunogene Therapy to Enhance Chemo-Immune Combination Treatments and Overcome Resistance to Osimertinib
Investor presentation to highlight novel gene therapies for cancer and diabetes
Investor presentations to highlight novel gene therapies for cancer and diabetes
Two Austin-based companies involved in medial research say they expect to raise millions of dollars with stock offerings this week.
Genprex has entered into securities purchase agreements with two healthcare-dedicated institutional investors for the purchase and sale of 4,000,000 shares of its common stock at a purchase price of $6.25 per share in a registered direct offering priced at-the-market under Nasdaq rules.
World reknowned medical and clinical experts to guide Genprex’ novel gene therapy clinical development programs in cancer and diabetes, including its two upcoming clinical trials in lung cancer
Joins Global Movement to Raise Awareness and Reduce the Burden of Cancer Worldwide
Mr. Redman provides his reaction to a recent article in ONCOLOGY® and discusses how Genprex is harnessing breakthroughs in lung cancer treatment.